TR201808037T4 - Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem. - Google Patents

Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem. Download PDF

Info

Publication number
TR201808037T4
TR201808037T4 TR2018/08037T TR201808037T TR201808037T4 TR 201808037 T4 TR201808037 T4 TR 201808037T4 TR 2018/08037 T TR2018/08037 T TR 2018/08037T TR 201808037 T TR201808037 T TR 201808037T TR 201808037 T4 TR201808037 T4 TR 201808037T4
Authority
TR
Turkey
Prior art keywords
hprt
subject
purine base
cells
deficient
Prior art date
Application number
TR2018/08037T
Other languages
English (en)
Turkish (tr)
Inventor
Kasahara Noriyuki
Robert Schiestl H
Hacke Katrin
Szakmary Akos
Gay Crooks M
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of TR201808037T4 publication Critical patent/TR201808037T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2018/08037T 2011-04-20 2012-04-20 Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem. TR201808037T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161477440P 2011-04-20 2011-04-20

Publications (1)

Publication Number Publication Date
TR201808037T4 true TR201808037T4 (tr) 2018-06-21

Family

ID=47041955

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/08037T TR201808037T4 (tr) 2011-04-20 2012-04-20 Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem.

Country Status (11)

Country Link
US (1) US9439928B2 (https=)
EP (3) EP3384912B1 (https=)
JP (4) JP5997257B2 (https=)
AU (3) AU2012245269B2 (https=)
CA (1) CA2861440C (https=)
DK (1) DK2699247T3 (https=)
ES (1) ES2672693T3 (https=)
PL (1) PL2699247T3 (https=)
RU (2) RU2611396C2 (https=)
TR (1) TR201808037T4 (https=)
WO (1) WO2012145723A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012245269B2 (en) * 2011-04-20 2016-09-29 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
US9682106B2 (en) * 2011-04-20 2017-06-20 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle
ES2909662T3 (es) * 2014-08-07 2022-05-09 Laevoroc Immunology Ag Composiciones que comprenden un inhibidor de PNP para uso en el tratamiento de la recaída de malignidad después de un trasplante de células madre hematopoyéticas
US20180140606A1 (en) * 2016-11-18 2018-05-24 Calimmune, Inc. In Vivo Chemoselection with Low Dose Thioguanine
JP6783674B2 (ja) 2017-01-20 2020-11-11 株式会社日立ハイテク 自動分析装置、自動分析装置における廃液方法、及び、三方電磁弁
WO2019018383A1 (en) * 2017-07-18 2019-01-24 Calimmune, Inc. COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES
CN111343996A (zh) 2017-07-18 2020-06-26 卡利门股份有限公司 用于选择供体修饰细胞的可调节开关
US12359200B2 (en) 2017-10-09 2025-07-15 Stowers Institute For Medical Research Methods and compositions for expansion of cell population
JP2022514955A (ja) * 2018-12-23 2022-02-16 シーエスエル・ベーリング・エルエルシー ウィスコット・アルドリッチ症候群の造血幹細胞遺伝子治療
BR112021012318A2 (pt) * 2018-12-23 2022-01-18 Csl Behring Llc Células t doadoras com interruptor de eliminação

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965126A (en) 1996-03-25 1999-10-12 The Penn State Research Foundation use of mutant alkyltransferases for gene therapy to protect from toxicity of therapeutic alkylating agents
WO1997043900A1 (en) * 1996-05-24 1997-11-27 The President And Fellows Of Harvard College In vivo selection
WO1998019540A1 (en) 1996-11-04 1998-05-14 Saint Jude Children's Research Hospital In vivo selection of primitive hematopoietic cells
US6558662B2 (en) * 1997-11-14 2003-05-06 The General Hospital Corporation Treatment of hematologic disorders
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
US7094885B2 (en) * 1999-07-11 2006-08-22 Neorx Corporation Skeletal-targeted radiation to treat bone-associated pathologies
US20030032003A1 (en) 2000-02-02 2003-02-13 Schiestl Robert H. In vivo selection
CA2428721A1 (en) * 2000-11-14 2002-05-23 The General Hospital Corporation Blockade of t cell migration into epithelial gvhd target tissues
US7037900B2 (en) * 2001-10-12 2006-05-02 Supergen, Inc. Composition and method for treating graft-versus-host disease
AU2012245269B2 (en) * 2011-04-20 2016-09-29 The Regents Of The University Of California Method for combined conditioning and chemoselection in a single cycle

Also Published As

Publication number Publication date
US20140154225A1 (en) 2014-06-05
CA2861440A1 (en) 2012-10-26
JP5997257B2 (ja) 2016-09-28
JP2014512391A (ja) 2014-05-22
PL2699247T3 (pl) 2018-09-28
RU2017104621A (ru) 2018-08-15
AU2018200967A1 (en) 2018-03-01
JP6266716B2 (ja) 2018-01-24
DK2699247T3 (en) 2018-06-14
EP2699247A1 (en) 2014-02-26
US9439928B2 (en) 2016-09-13
JP6799117B2 (ja) 2020-12-09
JP6560332B2 (ja) 2019-08-14
AU2018200967B2 (en) 2019-08-15
EP3384912B1 (en) 2020-11-11
JP2018044007A (ja) 2018-03-22
AU2012245269B2 (en) 2016-09-29
HK1256048A1 (en) 2019-09-13
EP2699247A4 (en) 2014-11-19
RU2728867C2 (ru) 2020-07-31
CA2861440C (en) 2022-11-15
RU2013151632A (ru) 2015-05-27
RU2611396C2 (ru) 2017-02-21
AU2016259368A1 (en) 2016-12-08
RU2017104621A3 (https=) 2020-06-04
JP2017008090A (ja) 2017-01-12
ES2672693T3 (es) 2018-06-15
AU2016259368B2 (en) 2017-12-14
EP3384912A1 (en) 2018-10-10
WO2012145723A1 (en) 2012-10-26
AU2012245269A1 (en) 2013-12-05
EP2699247B1 (en) 2018-03-07
EP3799876A1 (en) 2021-04-07
JP2019199476A (ja) 2019-11-21

Similar Documents

Publication Publication Date Title
TR201808037T4 (tr) Tek bir döngüde kombine koşullandırma ve kemo seçimine yönelik yöntem.
Li et al. Mn (III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin mitigates total body irradiation-induced long-term bone marrow suppression
EP3318276A1 (en) Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
Lin et al. Sirolimus augments hematopoietic stem and progenitor cell regeneration following hematopoietic insults
US11607427B2 (en) Method for chemoselection
Hacke et al. Combined preconditioning and in vivo chemoselection with 6-thioguanine alone achieves highly efficient reconstitution of normal hematopoiesis with HPRT-deficient bone marrow
JP2009514967A (ja) 幹細胞の加齢化を調節するための方法及び組成物
Zhou et al. Adenosine kinase gene modified mesenchymal stem cell transplantation retards seizure severity and associated cognitive impairment in a temporal lobe epilepsy rat model
HK1256048B (en) Method for combined conditioning and chemoselection in a single cycle
KR102099367B1 (ko) 불변 자연살해세포의 분화 조절기능을 갖는 ｌｄｂ１의 용도
KR20130023797A (ko) 자연살해세포 억제제 및 간엽줄기세포를 유효성분으로 포함하는 이식편대숙주질환의 예방 또는 치료를 위한 세포치료제 조성물
Burgos Espadinha Exploring combined treatment strategies to target quiescent chronic myeloid leukemia (CML) stem cells
CN119497573A (zh) 一种表达il-8的非人哺乳动物模型及其用途